Por: Shunping Gui1, Jin Jia1, Xiaoyu Niu, Yi Bai, Heng Zou, Juelin Deng y Rong Zhou. Journal of Renin-Angiotensin-Aldosterone System, March 2014 vol.
Hypertensive disorder of pregnancy is one of the most common perinatal diseases,1 accounting for about 10%-15% of pregnancies. It can be defined as the onset of hypertension after the 20th week of pregnancy, with systolic and diastolic pressure higher than 140 and 90 mm Hg on at least two different occasions.4 However, the pathogenesis of preeclampsia remains elusive, and prevention through routine supplementations with calcium, magnesium, omega-3 fatty acids, or antioxidant vitamins are ineffective.5??–8 To date, it is certain that pregnancy has been reported to be a state of relative arginine deficiency. Arginine is one kind of essential amino acid, physiologically active in L-form, which is synthesized by endothelial cells and excreted with urine in vivo. Arginine has been well recognized as a drug to treat variable diseases and symptoms, as well as a dietary tonic.
Por: Daisuke Mikami, Hideki Kimura, Kazuko Kamiyama, Kunio Torii, Kenji Kasuno, Naoki Takahashi, Haruyoshi Yoshida y Masayuki Iwano. Hypertension Research (2014) 37, 422–431.
Telmisartan, an angiotensin II receptor type 1 blocker (ARB), was recently reported to promote lipolysis in mice by acting as a peroxisome proliferator-activated receptor (PPAR)-d activator, although in clinical studies, it has also been recognized to activate PPAR-? as a major cause of its pleiotropic actions. The aim of this study was to investigate whether telmisartan activates endogenous PPAR-d and thereby exerts anti-fibrotic effects in human mesangial cells (HMC).
Efectos terapéuticos de la microdosis de captopril en la hipertensión arterial esencial
Por: Santana Téllez, Tomás Noel (2012). Tesis.repo.sld.cu/732, ( Repositorio de Tesis Doctorales)
Fundamento: Prescribir una terapéutica adecuada para un diagnóstico específico siempre es complejo, más cuando los índices de control clínico y la seguridad de los medicamentos que se utilizan en la actualidad no satisfacen tales objetivos. Objetivo: Demostrar los efectos de la microdosis de captopril administrada por vía bucal en el tratamiento de la hipertensión arterial esencial. Método: Se realizaron dos ensayos clínicos aleatorizados, unicéntricos, de grupos paralelos y controlados de eficacia y seguridad de la microdosis de captopril administrada por vía bucal en el tratamiento de la hipertensión arterial esencial. La investigación fue llevada a cabo en tres etapas, precedidas por una caracterización clínica, epidemiológica y terapéutica de los pacientes atendidos en una consulta especializada, creada al efecto en el Hospital Universitario Manuel Ascunce Domenech, de Camagüey; entre 2004 y 2009.
Comentarios recientes